News for Amneal Pharmaceuticals, Inc. (AMRX)

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc.

With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.

Summary Amneal Pharmaceuticals Inc (AMRX), a global biopharmaceutical company, announced on [date of press release] a donation of $1.5 million to various patien

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (”œAmneal” or the ”œCompany”), a global biopharmaceutical company, today announced donations totaling $1.5 mi

Amneal Pharmaceuticals, Inc. (AMRX), Monday announced data from a new analysis of the pivotal RISE-PD Phase 3 study, evaluating the efficacy and safety of CREXONT compared with IR CD/LD in the treatment of patients with Parkinson's disease or PD.

Key Highlights: Amneal Pharmaceuticals has expanded insurance coverage for Crexont, boosting reach from 30% to over 50% of insured U.S. lives. Analysts s

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (”œAmneal” or the ”œCompany”), a global biopharmaceutical company, today announced that three large insurance

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief Ex

Amneal Pharmaceuticals Inc (AMRX), a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics Lic

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript February 28, 2025Amneal Pharmaceuticals, Inc. misses on earnings expectations.

Revenue: $731 million in Q4, up 18%; $2.8 billion for full-year 2024, up 17% year-over-year.Adjusted EBITDA: $155 million in Q4; $627 million for full-year 202

Feb 28, 2025 / 01:30PM GMTOperator Thank you for your patience, everyone. The Amneal Pharmaceuticals fourth-quarter 2024 earnings conference call will begin sho

The following slide deck was published by Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ETCompany ParticipantsTony DiMeo - Head of Investor...

Amneal (AMRX) delivered earnings and revenue surprises of -20% and 3.15%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (”œAmneal” or the ”œCompany”) today announced its results for the fourth quarter and full year ended December

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.